Why the study?
Unlike other malignancies, transcriptomic signatures have not yet reached routine clinical use in soft tissue sarcomas despite limited treatment options and high recurrence rates.
Do transcriptomic biomarker signatures improve prognostication in patients with soft tissue sarcomas compared to standard histological grading?
Design
Review
Authors
Loading...
May refine STS prognostication beyond grading; hypothesis-generating and requires prospective validation before clinical adoption.
Do transcriptomic biomarker signatures improve prognostication in patients with soft tissue sarcomas compared to standard histological grading?
Transcriptomic signatures like CINSARC show promise in improving risk classification and prognostication in soft tissue sarcomas beyond traditional histological grading, though prospective validation is needed.
Merry et al. (2021) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: